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The airway diseases asthma and COPD affect millions of individuals worldwide.1 
These diseases are major determinants of chronic morbidity and mortality, and rep-
resent a substantial public health burden.2–4 Despite differences in etiology, clinical 
characteristics, and pathophysiology, both conditions share important features, such as 
airway obstruction and chronic airway inflammation. As a result of modern lifestyle, 
the incidence of both diseases is steadily increasing worldwide and effective preven-
tive and treatment strategies are unmet needs.5
Traditionally, airway eosinophilia has been regarded as a major hallmark of 
asthma, whereas COPD has been associated with neutrophilic airway inflammation.6 
For treatment of chronic inflammatory airway diseases, inhaled corticosteroids (ICS) 
are usually prescribed as maintenance therapy, most often as part of a combination 
therapy. While the majority of asthma patients generally respond well to ICS,7 this is 
not often the case in COPD.8 Hence, reliable algorithms and easily implemented tools 
are needed to identify ICS responders in clinical practice, to optimize clinical benefits 
and minimize adverse events.
Over the past two decades, increasing insights into the pathobiology of chronic 
airway disease have enabled an understanding of its heterogeneous nature and thus 
helped to shape precision medicine.9 These novel insights are gradually being adapted 
by (inter)national guidelines for disease management in daily practice. In asthma, 
this has – among others – resulted in adding targeted therapies with biologicals for 
refractory allergic and/or eosinophilic asthma at treatment step 5 and, more recently, 
in adding house dust mite (HDM) sublingual immunotherapy for HDM-sensitized 
asthma patients uncontrolled on standard therapy in steps 3 and 4.3
Until recently, the Global Initiative for Obstructive Lung Disease (GOLD) strategy 
did not differentiate across the COPD spectrum.10 For example, the GOLD-D category 
comprised three different phenotypes, ie, patients with a severe airway obstruction or 
frequent exacerbations, or both. Recent advances have led to the recognition that these 
different subsets may require different treatment approaches instead of the “one-size 
fits all” ICS-containing therapy as advocated in the treatment strategy at that time.10 
This has resulted in default prescription of ICS for COPD patients.8
Increasing evidence of limited clinical effectiveness in distinct phenotypes,11–14 
along with safety concerns associated with long-term use of high-dose ICS,15,33 has 
driven a personalized treatment strategy for chronic inflammatory airway disease 
recently proposed by an international expert panel.16
Precision medicine is the cornerstone of this innovative approach advocating 
identification and treatment of “treatable traits” in individual patients.17,18 In this 
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context, blood eosinophils as indicators of eosinophilic 
exacerbations have been identified as a “treatable trait”.19,20 
Data from several studies showed that benefits from ICS in 
COPD were limited to patients with frequent exacerbations 
and blood eosinophilia (the higher the initial blood eosinophil 
count the more the benefit).13,21 The recently updated GOLD 
classification is based on symptoms and exacerbations and 
hence provides a more differentiated treatment algorithm.22 
Consequently, ICS therapy is only recommended for patients 
with frequent exacerbations uncontrolled on a combination 
of bronchodilators (ie, GOLD C and D).22 In this paper, we 
will provide a rationale toward more effective ICS prescrip-
tion for patients with chronic inflammatory airway disease 
based on treatable traits.
Over-prescription of inhaled 
corticosteroids in chronic 
inflammatory airway disease
ICS have been available to treat chronic inflammatory 
airway disease for almost 70 years.23 Consequently, ICS-
containing treatments have been amongst the most commonly 
prescribed and thus most profitable medications.24 This has 
enabled pharmaceutical companies to further develop this 
area of therapeutics. However, despite a massive level of 
prescription of (optimized) ICS and long-acting beta-agonist 
(LABA) combinations, many patients remain suboptimally 
controlled,25,26 with only small changes in morbidity and mor-
tality of both asthma and COPD, while numbers of hospital 
admissions continue to rise increasing health care costs as 
a consequence.27 Although this may partly be ascribed to 
an increase in the prevalence of both conditions, we cannot 
attribute the clinical reality to this factor alone. Is it possible 
that many of the patients treated with ICS are either non-
responsive or respond suboptimally to this treatment?
Dogmatic prescription of ICS in chronic airway disease 
has resulted in a significant level of over-prescription.28 
In asthma, awareness of the potential for a customized 
approach to ICS prescription has been incorporated into the 
guidelines advocating a step-down regime after control has 
been reached. Moreover, guidelines now accept a role for a 
more flexible maintenance and rescue from the use of ICS/
LABA combinations.29 In COPD, the efficacy of ICS therapy 
has been investigated for over 25 years now. Initially, it was 
assumed that the benefits seen in many asthma patients would 
be transferrable to those with COPD. Large scale studies 
were performed with high doses of ICS, all of which were 
either negative or demonstrated modest benefits at best.30 No 
protection was observed against a decline in lung function 
and overall, only modest effects on exacerbations and qual-
ity of life were seen.31 Despite these findings, in clinical 
practice, ICS continued to be prescribed to COPD patients 
at every level of lung function deficit and for every disease 
category as defined by the GOLD approach.8 Moreover, 
ICS are prescribed for at least 40% of smokers present-
ing with symptoms without any measurable lung function 
abnormality.28,32 In these individuals, there is no evidence to 
support the use of ICS.
The results of the over-prescription of ICS affect all par-
ties involved. First, the individuals treated erroneously are 
being exposed to medication they do not actually need along 
with the potential for side effects (eg, oropharyngeal candidi-
asis, dysphonia, skin bruising, osteoporosis, cataract, loss of 
diabetic control, and pneumonia).33–35 Second, the prescribers 
feel that they are treating their patient and thus do not reflect 
on other – more effective – therapies, and, finally, the insur-
ance ends up paying for ineffective medication and is thus 
unable to fund much more cost-effective approaches in the 
long term (smoking cessation, bronchodilators, pulmonary 
rehabilitation).
Prescribing ICS on a “one size fits all basis” could be 
justified in the early years because this was the only available 
medication option. Presently, prescribing by default is no 
longer acceptable and a more personalized approach based 
on treatable traits should be encouraged.
From “one size fits all” toward 
personalized treatment
In many ways, proposing a more precise approach to the 
prescription of ICS may seem contradictory, as corticoster-
oids are a non-precise treatment by their very mechanism 
of action. Nevertheless, it is crucial for physicians to appro-
priately prescribe ICS to ensure effectiveness and limit side 
effects. Both for asthma and COPD, utilizing biomarkers has 
been shown to aid the diagnosis, to predict exacerbations and 
to drive treatment.36,37 In this respect, fractionated exhaled 
nitric oxide (FeNO) and blood eosinophils are easily measur-
able biomarkers that can be used to predict and to monitor 
treatment response and adherence to ICS.16,38,39
Currently, there is increasing understanding that both 
asthma and COPD are heterogeneous disorders with over-
lapping characteristics.3,9,18 Even though at times they may 
appear to be clinically indistinguishable, cluster analyses 
have identified distinct clinical, biological, and pathological 
clusters with different responses to treatment.7,20,40–43 Impor-
tantly, cluster analyses can link inflammatory phenotypes to 
treatment algorithms. For instance, the hierarchical cluster 
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analysis by Haldar et al on data from over 400 asthma 
patients revealed five different phenotypic clusters based on 
concordance between symptoms, sputum eosinophilia, and 
the response to ICS.7
Patients with concordant symptoms and sputum eosino-
philia presented with milder, often atopic disease, with an 
overall good response to ICS and a benign disease course, 
while those with discordant symptoms or inflammation usu-
ally presented with a more complex disease with varying 
response to ICS. Similar observations have been previously 
made in a number of clinical studies.44,45 Overall, these find-
ings support a symptom-guided approach to management 
for mild to moderate, “concordant”-type asthma, while 
“discordant”-type, refractory asthmatics might benefit from 
inflammatory biomarker-guided, personalized therapeutic 
options including targeted therapy with biologics.
How do these findings relate to COPD? ISOLDE was 
one of the first studies to investigate the effect of ICS on 
the rate of decline in lung function in COPD patients. The 
study was negative for its primary end point.31 However, 
data from a post hoc analysis of the ISOLDE study revealed 
that patients with moderate to severe COPD with persistent 
blood eosinophilia of 2% show an accelerated lung function 
decline that can be prevented by ICS treatment, while ICS 
did not affect lung function decline in patients with blood 
eosinophila 2%.46 This compelling evidence in combina-
tion with novel insights into underlying disease mechanisms 
urged a panel of international experts to propose a person-
alized approach to chronic inflammatory airway disease 
management beyond clinical labels.17,18 Hence, the concept 
of “treatable traits” was conceived, implementing precision 
medicine into clinical practice.
These insights based on emerging data from large 
clinical trials helped to further shape the updated GOLD 
strategy.22 This update has reclassified COPD and empha-
sizes the dual goals of symptom control and reduction in risk 
of exacerbation. Presently, optimal bronchodilator therapy, 
often comprising a LABA with a long-acting muscarinic 
antagonist (LAMA) in a fixed dose combination (FDC), 
is the cornerstone of COPD treatment.22 This combination 
treatment decreases both the static and dynamic hyperinfla-
tion, which helps to optimize lung function, daily activities, 
to improve exercise capacity and endurance, and the overall 
quality of life.47–49 LABA–LAMA bronchodilator combina-
tion therapy has been recommended based on the outcomes 
of large randomized controlled trials including the recently 
published FLAME study.50 This large prospective study 
showed superiority of the LABA–LAMA combination in 
preventing exacerbations in patients with COPD as com-
pared to those on a fixed ICS–LABA combination, irrespec-
tive of baseline blood eosinophils.51 The study had tightly 
controlled inclusion criteria which excluded participants 
with baseline eosinophils 600 cells/µL, and the run-in 
period excluded ICS with the potential that eosinophilic 
participants will become unstable and be excluded. Dur-
ing this 52-week study, the incidence of pneumonia was 
significantly higher in patients on ICS–LABA compared 
to those on LABA–LAMA combination (4.8% vs 3.2%, 
p=0.02). These findings are in line with previous large stud-
ies investigating the effect of ICS (containing) therapy on 
exacerbations, lung function decline, and mortality in COPD 
which could not demonstrate substantial or additional clini-
cal benefits of ICS in many patients over time.31,51–54 Several 
other studies have examined the risk benefit of the use of 
ICS and also ICS withdrawal.16,53–59 Specifically, during the 
12-month study (WISDOM) that included patients with 
(very) severe COPD taking tiotropium plus salmeterol, 
the risk of moderate or severe exacerbations was similar 
among those who discontinued ICS and those on ICS co-
treatment.52 A recent post hoc analysis showed that only 
patients with at least one exacerbation in the previous year 
and a high blood eosinophil count (ie, 300 cells/µL or 
4%) at baseline were at increased risk of an exacerbation 
after complete ICS withdrawal, representing a minority 
of the entire study population (n=2296).58 Indeed, other 
studies confirmed that blood eosinophils may further help 
to identify COPD patients with frequent exacerbations 
as a distinct phenotype that may benefit from ICS, while 
eosinophilic airway inflammation has been proposed as a 
“treatable trait”.8,17,20,59
Consequently, it is crucial to critically assess the benefits 
versus risks in the individual COPD patient and positively 
prescribe ICS based on phenotype-related treatable traits.17,18 
The updated GOLD strategy now better reflects this person-
alized approach.22
Changing of guidelines?
The future management of inflammatory airways disease is 
potentially very exciting. We believe that given the ample 
supportive evidence, which is shaping the current guidelines, 
the journey toward a “treatable trait” approach can really 
start. Our goal must be to give more effective therapy to 
patients who will respond – this applies not only to targeted 
treatments with biologic agents or small molecules but 
also existing therapy with ICS – and thus improve disease 
outcome while reducing the side effects of unnecessary 
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pharmacotherapy. An aspirational goal should be to never 
have to prescribe oral corticosteroids again to any patient 
with a proven inflammatory airways disease.16
To be able to move forward, we need to have a clear 
and accurate diagnosis. Focusing on obtaining information 
as to the individual patient’s symptoms, comorbidities and 
pathophysiology (clinical phenotype) complemented with the 
inflammatory phenotype. Based on these individual charac-
teristics, the correct treatment can be initiated. Presently, ICS 
with or without the addition of LABA are considered the basis 
of asthma pharmaceutical treatment. Comorbidities should be 
treated, and treatment should be adjusted/reconsidered with 
the goal of achieving optimal control of symptoms, reducing 
the risk of acute exacerbations and improving the patient’s 
daily activities/quality of life.
COPD treatment goals are similar: improving symptoms 
(dyspnea), reducing the risk of acute exacerbations, and 
improving quality of life. Apart from pharmacotherapy, 
non-drug treatment modalities are helpful to achieve optimal 
outcomes in COPD patients. Smoking cessation is essential 
in combination with bronchodilator therapy, to improve 
dyspnea, while the opportunity for pulmonary rehabilita-
tion should not be missed. Although challenging to many 
patients, pulmonary rehabilitation and necessary lifestyle 
adjustments are often critical to improve and reverse loss of 
lung function and exercise endurance. Bronchodilator therapy 
in COPD should always be optimized, ie, a combination of 
a LAMA and a LABA, now available as a FDC. Finally, 
based on the clinical phenotype stratification according to 
GOLD, we should make further treatment decisions based 
upon a detailed assessment of the underlying inflammatory 
mechanisms (inflammatory phenotype). Clinical (GOLD) 
phenotype should, at present, be given primacy when mak-
ing decisions to intensify therapy – especially moving triple 
therapy with ICS – as we lack definitive prospective data as 
to the utility of a true focused “treatable trait” prescription 
approach. However, it is clear that simply measurable and 
available biomarkers such as FeNO and blood eosinophil 
counts may help to predict a favorable response to ICS not 
only in asthma but also in COPD. More biomarkers will 
emerge and the use of a composite approach may have even 
more clinical utility, leading to mechanistic insights as well 
as directing disease modifying therapy such as new biological 
agents and small molecule inhibitors of specific inflamma-
tory pathway targets.
In summary, our goals for patients with asthma should 
be: to have minimal (none) symptoms, be free of restrictions 
in daily activities, and patients should never die of their dis-
ease. All patients should have their treatment titrated to the 
lowest level required to achieve and maintain these goals. 
COPD patients should be treated with the goal of reversing 
the disability that years of accelerated lung function decline 
have caused with a reduction in risk of exacerbations. This 
will be best achieved by a personalized approach, leading 
to an individual understanding of risks and benefits. The 
correct treatments should be given to the patients who 
will achieve the maximum benefit with the minimum risk. 
With current therapies, such management goals are within 
our grasp, although taking an individualized approach to 
management will maximize benefit and minimize risk.
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